MedDataX Logo

Trial Outcomes & Findings for HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone) (NCT NCT01023620)

NCT ID: NCT01023620

Last Updated: 2019-10-08

Results Overview

No data are available for this study as the PI has left the institution. Multiple efforts to contact the PI for the relevant data have failed

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

4 participants

Primary outcome timeframe

16 weeks

Results posted on

2019-10-08

Participant Flow

No data are available for this study as the PI has left the institution. Multiple efforts to contact the PI for the relevant data have failed.

Participant milestones

Participant milestones
Measure
Pioglitazone
10 male patients with lipodystrophy taking daily Pioglitazone 45 mg Pioglitazone: Participants will take oral Pioglitazone 45 mg daily for 16 weeks.
Observation/Comparison
10 male patients with lipodystrophy not taking daily Pioglitazone Observation: Participants will be observed for 16 weeks but will not receive drug
Overall Study
STARTED
0
0
Overall Study
COMPLETED
0
0
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)

Baseline characteristics by cohort

Baseline data not reported

PRIMARY outcome

Timeframe: 16 weeks

Population: No data are available for this study as the PI has left the institution. Multiple efforts to contact the PI for the relevant data have failed

No data are available for this study as the PI has left the institution. Multiple efforts to contact the PI for the relevant data have failed

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 16 weeks

Population: Investigator left the university mid way through the study and unable to find him.

Outcome measures

Outcome data not reported

Adverse Events

Pioglitazone

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Observation/Comparison

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Michael Limerick

UT Southwestern Medical Center

Phone: 214-590-0611

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place